August 2012
-
Device company Nemera has announced the promotion of the leader of its Innovation Center, Dimitri Grasswill, to VP of Innovation. Grasswill has directed the Innovation Center, located in La Verpillière, France, since 2013. In a… Read more . . .
-
The FDA has approved Promius Pharma’s Tosymra sumatriptan nasal spray (formerly known as DFN-02) for the treatment of migraine, Promius parent company Dr. Reddy’s has announced. The company submitted an NDA for the nasal spray… Read more . . .
-
CDMO Hovione has announced that it issued a $50 million bond, arranged and subscribed by Banco BPI, that is set to mature in 2033 in order to finance an expansion of its production capacity. The company has… Read more . . .
-
Circassia Pharmaceuticals will pay AIT Therapeutics $7.35 million up front plus potential milestone payments and royalties for the exclusive rights to commercialize AIT’s AirNOvent ventilator compatible nitric oxide in the US and China, the company… Read more . . .
-
Ziccum, a spin out from Inhalation Sciences, has announced that it submitted a patent application for a temperature-stable dry powder formulation of adenovirus. According to the company, the formulation, which would be suitable for delivery… Read more . . .
-
FDA Commissioner Scott Gottlieb has issued a statement detailing steps that the agency is taking to encourage development of an over the counter naloxone nasal spray, including the publication of a model drug facts label… Read more . . .
-
Dance Biopharm, which is developing an insulin soft mist inhaler, has named Melissa Rhodes as Chief Development Officer and Michael Kaseta as its new Chief Financial Officer. The company said that former CFO Don Huffman… Read more . . .
-
Inhaler filling experts Harro Höfliger have announced a number of management changes after the retirement of its founder, Harro Höfliger, who has been succeeded by his son, Markus Höfliger as Chairman of the Supervisory Board.… Read more . . .
-
MannKind Corporation has announced that it will offer Afrezza inhaled insulin directly to diabetes patients in the US and is also introducing a savings card program for US patients with commercial insurance . The direct… Read more . . .
-
US-based StellaPharma has announced that it will acquire G2B Pharma (G2B) and its dry powder nasal formulation of epinephrine for the treatment of anaphylaxis. According to a 2014 press release, G2B had licensed SNBL’s nasal… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.